Chimeric Antigen Receptors (CARs) for Advanced Therapies

Project Information

CARAT

Grant agreement ID: 667980

DOI

10.3030/667980

Project closed

EC signature date 8 December 2015

Start date 1 January 2016

End date 31 December 2019

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 5 989 158,75

EU contribution

€ 5 989 158,75

Coordinated by

MILTENYI BIOTEC BV & CO KG
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (6)

Report on ethical issues relevant to CAR T-cell therapies

Report on ethical issues relevant to CAR T-cell therapies

Report on proceedings of a workshop on regulatory issues
Optimized integrated CAR T-cell process validated by manufacturing centres
Report on results of survey
"Report on implementation of ""CAR sharing"""
Open access summary report

Websites, patent fillings, videos etc. (1)

Project website

Publications

Peer reviewed articles (5)

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use

Author(s): Dominik Lock, Nadine Mockel-Tenbrinck, Katharina Drechsel, Carola Barth, Daniela Mauer, Thomas Schaser, Carolin Kolbe, Wael Al Rawashdeh, Janina Brauner, Olaf Hardt, Natali Pflug, Udo Holtick, Peter Borchmann, Mario Assenmacher, Andrew Kaiser
Published in: Human Gene Therapy, Issue 28/10, 2017, Page(s) 914-925, ISSN 1043-0342
Publisher: Mary Ann Liebert Inc.
DOI: 10.1089/hum.2017.111

<em>Ex Vivo</em> Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy

Author(s): Elisa Peranzoni, Houcine Bougherara, Sarah Barrin, Audrey Mansuet-Lupo, Marco Alifano, Diane Damotte, Emmanuel Donnadieu
Published in: Journal of Visualized Experiments, Issue 130, 2017, ISSN 1940-087X
Publisher: MYJoVE Corporation
DOI: 10.3791/55709

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors

Author(s): Johanna Reul, Janina Frisch, Christine E. Engeland, Frederic B. Thalheimer, Jessica Hartmann, Guy Ungerechts, Christian J. Buchholz
Published in: Frontiers in Oncology, Issue 9, 2019, ISSN 2234-943X
Publisher: Frontiers Media S. A.
DOI: 10.3389/fonc.2019.00052

Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing

Author(s): Constanze Radek, Ornellie Bernadin, Katharina Drechsel, Nicole Cordes, Rita Pfeifer, Pia Sträßer, Mirella Mormin, Alejandra Gutierrez-Guerrero, François-loïc Cosset, Andrew D. Kaiser, Thomas Schaser, Anne Galy, Els Verhoeyen, Ian C.D. Johnston
Published in: Human Gene Therapy, Issue 30/12, 2019, Page(s) 1477-1493, ISSN 1043-0342
Publisher: Mary Ann Liebert Inc.
DOI: 10.1089/hum.2019.157

Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts

Author(s): Jessica Hartmann, Martina Schüßler‐Lenz, Attilio Bondanza, Christian J Buchholz
Published in: EMBO Molecular Medicine, 2017, Page(s) e201607485, ISSN 1757-4676
Publisher: John Wiley & Sons Ltd.
DOI: 10.15252/emmm.201607485

Intellectual Property Rights

Patent (1)

CHIMERIC ANTIGEN RECEPTORS THAT BIND TO PROSTATE SPECIFIC MEMBRANE ANTIGEN

Application/Publication number: 18 180026
Date: 2018-06-27
Applicant(s): UNIVERSITAETSKLINIKUM FREIBURG